Dr. Huang Huiqiang: Immune Therapy Era is Imminent for Extranodal NK/T Cell Lymphoma
Extranodal NK/T cell lymphoma (ENKTCL), nasal type, is a rare subtype prevalent in Asian populations and associated with the Epstein-Barr virus (EBV). Currently, patients' prognosis remains poor, especially for relapsed/refractory (R/R) cases. From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) Annual Congress was held in Frankfurt, Germany. A selected oral presentation (Abstract No: S226) revealed significant efficacy in treating R/R ENKTCL patients with PD-1 inhibitors alone or in combination. This study once again confirms that immune checkpoint inhibitors have become a crucial therapeutic approach for R/R ENKTCL patients. Oncology Frontier had the privilege of inviting Dr. Huang Huiqiang from Sun Yat-sen University Cancer Center, China, to share the results and insights from this research at the conference.